Oval Abutment Versus a Circular Abutment in Dental Implants in the Anterior Maxillae

Sponsor
Ana María García de la Fuente (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05642520
Collaborator
(none)
40
1
2
60
0.7

Study Details

Study Description

Brief Summary

Objetive: The main objective of this clinical trial is to assess whether the oval section abutment of a 2.9mm implant achieves a greater covering of the tooth-implant papilla compared to a circular section abutment in 3.3mm implants in upper lateral incisors and lower central / lateral incisors.

Material and methods: fourty patients received unitary implants of 3.3mm or 2.9 mm diameter to replace the absence of upper lateral incisor or lower central/lateral incisor with an edentulous space of at least 6.4mm (mesio-distally). Esthetic and clinical parameters were evaluated 12 months after installation of the prosthesis.

Condition or disease: dental implants

Intervention/treatment: 3.3 or 2.9 mm diameter dental implants

Phase: Not Applicable

Condition or Disease Intervention/Treatment Phase
  • Procedure: Oval section abutment of 2.9 mm
  • Procedure: Circular section abutment of 3.3 mm
N/A

Detailed Description

The study was a double-blind controlled clinical trial (RCT) comparing the oval section abutment of a 2.9mm (test group) to a circular section abutment in 3.3mm (control group) implants for the replacement of a single tooth.

The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed, while if the width ranged between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).

The main objective was the papillary index (PI) (Jemt, 1997). It consists in four scores: 0 = absence of interdental papilla; 1 = filling of the interdental space less than 50% of the soft tissues; 2 = filling of the interdental space greater than 50% of the soft tissues; 3 = total filling of the interdental space with good aesthetic harmony; 4 = Hyperplasic interdental papilla formation with irregular soft tissue. Both mesial and distal papilla will be recorded.

The secondary objectives are (a) to observe the stability of the soft and hard tissues after one year in function, (b) to assess the success and survival rate of the implants, (c) to assess the stability of the implants and their evolution and (d) to analyze the degree of patient satisfaction with the aesthetic result.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study was a double-blind controlled clinical trial (RCT) comparing the oval section abutment of a 2.9mm (test group) to a circular section abutment in 3.3mm (control group) implants for the replacement of a single tooth. The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed, while if the width ranged between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).The study was a double-blind controlled clinical trial (RCT) comparing the oval section abutment of a 2.9mm (test group) to a circular section abutment in 3.3mm (control group) implants for the replacement of a single tooth. The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed, while if the width ranged between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
The clinical monitor will hide the treatment to the clinical observer, the patient and the statistician.
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Clinical Trial Comparing the Placement of an Oval Abutment in 2.9 mm Implants Versus a Circular Abutment in Implants of 3.3 mm to 12 Months of Evolution
Actual Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: oval section abutment of a 2.9mm

The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).

Procedure: Circular section abutment of 3.3 mm
The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
Other Names:
  • Prosthetic treatment over a circular section abutment of 3.3.mm
  • Placebo Comparator: circular section abutment in 3.3mm

    The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).

    Procedure: Oval section abutment of 2.9 mm
    The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).

    Outcome Measures

    Primary Outcome Measures

    1. The main objective was the papillary index (PI) (Jemt, 1997) [12 months]

      It consists in four scores: 0 = absence of interdental papilla; 1 = filling of the interdental space less than 50% of the soft tissues; 2 = filling of the interdental space greater than 50% of the soft tissues; 3 = total filling of the interdental space with good aesthetic harmony; 4 = Hyperplasic interdental papilla formation with irregular soft tissue. Both mesial and distal papilla will be recorded.

    Secondary Outcome Measures

    1. To observe the stability of the soft and hard tissues after one year in function: probing depth [12 months]

      Probing depth (PD), defined as the distance (mm) between the most apical point of the gingival sulcus or periodontal pocket and the free gingival margin. It will be taken at six points per tooth and in four points by implant.

    2. To observe the stability of the soft and hard tissues after one year in function:bleeding on probing [12 months]

      Bleeding on probing (BP) (Ainamo and Bay 1975), presence of bleeding in six points per tooth (3 in vestibular and 3 in lingual or palatal).

    3. To observe the stability of the soft and hard tissues after one year in function: suppuration on probing [12 months]

      Suppuration on probing, presence of pus within 15 seconds after probing.

    4. To observe the stability of the soft and hard tissues after one year in function: Modified plaque index (MPI) [12 months]

      Modified plaque index (MPI) (Mombelli et al 1987): 0 = no plaque detected; 1 = detection of plaque when a periodontal probe passes over the surface of the implant; 2 = the plaque is visible to the naked eye; 3 = abundant plate.

    5. Assessment of survival rate of the implants [12 months]

      The survival rate of the implants will be recorded taking into consideration Albrektsson et al.´s criteria. (Albrektson et al 1986)

    6. Assessment of the success of the implants [12 months]

      The implant will be considered successful when: (a) non-detectable clinical mobility (manual test); (b) absence of radiolucency around the surface of the implant; (c) absence of persistent pain; (d) absence of recurrent peri-implant infection. (Buser et al. 1990)

    7. Analyze the degree of patient satisfaction with the aesthetic result. [12 months]

      Visual analog scale (VAS): the general patient satisfaction will be evaluated. The specific satisfaction with respect to 5 parameters will also be recorded - aesthetics, mastication, phonation, comfort and self-esteem - using 10 cm visual analog scales calibrated with the terms "nothing satisfied" and "totally satisfied" at the left and right ends respectively.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients >18 years of age

    • Absence of upper lateral incisors or lower central / lateral incisors with an edentulous space of at least 6.4mm (mesio-distally).

    • The teeth adjacent to the edentulous space must be natural.

    • Patients who are in periodontal health.

    • Signing of informed consent before entering the study.

    Exclusion Criteria:
    • Patients with any systemic condition or disease that may interfere with oral surgery.

    • History of radiotherapy.

    • Patients smoking more than 20 cigarettes per day.

    • Pregnant or breastfeeding patients.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Stomatology II. UPV/EHU Leioa Biscay Spain 48940

    Sponsors and Collaborators

    • Ana María García de la Fuente

    Investigators

    • Principal Investigator: ANA MARIA GARCIA DE LA FUENTE, PhD, University of the Basque Country (UPV/EHU)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ana María García de la Fuente, Professor, University of the Basque Country (UPV/EHU)
    ClinicalTrials.gov Identifier:
    NCT05642520
    Other Study ID Numbers:
    • 2018_01
    First Posted:
    Dec 8, 2022
    Last Update Posted:
    Dec 28, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Dec 28, 2022